|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
BEFREE |
Our findings contribute to the understanding of the molecular mechanisms underlying insulin resistance and type 2 diabetes and point to inhibition of ADAMTS9 as a potential novel mode of treating insulin resistance.
|
30626608 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Three SNPs in ADAMTS9 were nominally associated with increased risk of T2DM (rs17070905, Odds Ratio (OR) = 2.30, 95% confidence interval (CI) 1.17-4.50; rs17070967, OR = 2.02, 95%CI 1.00-4.06; rs6766801, OR = 2.33, 95%CI 1.18-4.60), but these associations did not reach the statistical significance after adjusting for multiple comparisons.
|
23967108 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
CTD_human |
Three SNPs in ADAMTS9 were nominally associated with increased risk of T2DM (rs17070905, Odds Ratio (OR) = 2.30, 95% confidence interval (CI) 1.17-4.50; rs17070967, OR = 2.02, 95%CI 1.00-4.06; rs6766801, OR = 2.33, 95%CI 1.18-4.60), but these associations did not reach the statistical significance after adjusting for multiple comparisons.
|
23967108 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
BEFREE |
PPARG2 and ADAMTS9 variants are both associated with T2DM and with insulin resistance, whereas only ADAMTS9 may be related to βF.
|
23161442 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
To examine the association of type 2 diabetes susceptibility loci and visceral fat accumulation, we genotyped 1279 Japanese subjects (556 men and 723 women), who underwent computed tomography for measurements of visceral fat area (VFA) and subcutaneous fat area (SFA) for the following single-nucleotide polymorphisms (SNPs): NOTCH2 rs10923931, THADA rs7578597, PPARG rs1801282, ADAMTS9 rs4607103, IGF2BP2 rs1470579, VEGFA rs9472138, JAZF1 rs864745, CDKN2A/CDKN2B rs564398 and rs10811661, HHEX rs1111875 and rs5015480, TCF7L2 rs7901695, KCNQ1 rs2237892, KCNJ11 rs5215 and rs5219, EXT2 rs1113132, rs11037909, and rs3740878, MTNR1B rs10830963, DCD rs1153188, TSPAN8/LGR5 rs7961581, and FTO rs8050136 and rs9939609.
|
22377712 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
BEFREE |
Several genetic loci (JAZF1, CDC123/CAMK1D, TSPAN8/LGR5, ADAMTS9, VEGFA and HHEX-IDE) were identified to be significantly related to the risk of type 2 diabetes and quantitative metabolic traits in European populations.
|
20927120 |
2010 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
BEFREE |
Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients--EUGENE2 study.
|
19789630 |
2009 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
Biomarker
|
disease |
CTD_human |
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.
|
18372903 |
2008 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the impact on diabetes-related intermediary traits of common novel type 2 diabetes-associated variants in the JAZF1 (rs864745), CDC123/CAMK1D (rs12779790), TSPAN8 (rs7961581), THADA (rs7578597), ADAMTS9 (rs4607103), and NOTCH2 (rs10923931) loci, which were recently identified by meta-analysis of genome-wide association data.
|
18567820 |
2008 |
|
Nephronophthisis, familial juvenile
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Mutations of ADAMTS9 Cause Nephronophthisis-Related Ciliopathy.
|
30609407 |
2019 |
|
Waist-Hip Ratio
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer.
|
29193730 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adaptive sequence convergence of the tumor suppressor ADAMTS9 between small-bodied mammals displaying exceptional longevity.
|
28244876 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whether ADAMTS9 can function as a tumor suppressor gene (TSG) in colorectal cancer is still unclear.
|
29186710 |
2017 |
|
Asthma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study in Spanish identifies ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9), as a novel asthma susceptibility gene.
|
26620591 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A lncRNA, ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9) antisense RNA 2 (ADAMTS9-AS2), with unknown function, is the antisense transcript of tumor suppressor ADAMTS9.
|
24833086 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ADAMTS9 was reported to be a novel tumor suppressor gene and is downregulated in various types of human cancer due to hypermethylation of promoter CpG islands.
|
23358566 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The increase in ADAMTS9 expression can be a useful factor in the prevention of possible metastasis in breast cancer and for the occurrence of a tumor suppressive effect.
|
23690187 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further revealed that ADAMTS9 inhibited tumor growth by blocking activation of Akt and its downstream target the mammalian target of rapamycin (mTOR).
|
22907434 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, when congenic with the C57Bl/6 strain, 80% of ADAMTS9+/- mice developed spontaneous corneal neovascularization. beta-Galactosidase staining enabled by a lacZ cassette targeted to the ADAMTS9 locus showed that capillary endothelial cells (ECs) in embryonic and adult tissues and in capillaries growing into heterotopic tumors expressed ADAMTS9.
|
20093484 |
2010 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The present study is novel in evaluating the prevalence of ADAMTS9 methylation based on a large number of tumor samples and showing that epigenetic regulation of ADAMTS9 was associated with carcinogenesis.
|
19963134 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results indicate that ADAMTS9 contributes an important function in the tumor microenvironment that acts to inhibit angiogenesis and tumor growth in both ESCC and NPC.
|
20551050 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The combined microarray technologies suggested novel candidate oncogenes, amplification of GPR160 and SKIL at 3q26.2-q26.32, and deletion of tumor suppressor genes ADAMTS9 and LRIG1 at 3p12.3-p14.2.
|
19815638 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ADAMTS9 expression was downregulated or lost in 17 of 23 (73.9%) lymph node metastatic NPC specimens, which was significantly higher than in 14 of 43 (32.6%) primary tumors.
|
18449890 |
2008 |